# US 2024/0189479 A1 · Cardiovascular Prostheses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189479 A1
- Document ID: US20240189479A1
- Status: Published application
- Kind: A1
- Application number: 18/442,571
- Filed: 2024-02-15
- Published: 2024-06-13
- Earliest claimed: 2010-12-20
- Assignees: CorMatrix Cardiovascular, Inc.
- Applicants: CorMatrix Cardiovascular, Inc.
- Inventors: Robert G. Matheny
- Web page: https://patentgrep.com/patent/US20240189479A1

## CPC

- A61L 27/3633: {Extracellular matrix [ECM]}
- A61F 2/00: Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (dental prostheses A61C13/00; artificial kidneys A61M1/14; artificial hearts A61M60/00)
- A61F 2/0095: {Packages or dispensers for prostheses or other implants (for intraocular lenses A61F2/1691; for dental surgery A61C19/02)}
- A61F 2/06: Blood vessels
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/34: Macromolecular materials
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/507: {for artificial blood vessels (apparatus for applying cells on a blood vessel prosthesis A61F2/062)}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- A61F 2/0063: {Implantable repair or support meshes, e.g. hernia meshes}
- A61F 2/02: Prostheses implantable into the body
- A61F 2/062: {Apparatus for the production of blood vessels made from natural tissue or with layers of living cells}
- A61F 2210/0004: bioabsorbable
- A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body
- A61L 2300/406: Antibiotics
- A61L 2300/414: Growth factors
- A61L 2430/20: for reconstruction of the heart, e.g. heart valves
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are cardiovascular prostheses tissue that are formed from acellular extracellular matrix (ECM), an ECM-mimicking composition, or a combination thereof. The cardiovascular prostheses also comprise poly(glycerol sebacate) (PGS) and various antibiotics, cytokines, exosomes, growth factors, and/or everolimus. In some embodiments, the cardiovascular prostheses involves a plurality of particulate structures having an acellular ECM core and an outer layer or coating PGS and everolimus. Also disclosed are cardiovascular prostheses having particulate structures that include a decellularized placental tissue and a polymer component that includes poly(glycerol sebacate) (PGS).

## Claims

### Claim 1

A prosthesis for treating damaged biological tissue, comprising:
a mesh structure comprising a plurality of fibers comprising an extracellular matrix (ECM) composition comprising acellular ECM from a mammalian tissue source and at least one antibiotic selected from the group consisting of vancomycin and gentamicin,
each of said plurality of fibers comprising an outer surface,
said plurality of ECM fibers comprising a coating disposed on said outer surface, said coating comprising a composition comprising poly(glycerol sebacate) (PGS).

### Claim 2 (depends on 1)

The prosthesis of claim 1, wherein said mammalian tissue source comprises tissue selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), mesothelial tissue, placental tissue, cardiac tissue, kidney tissue and omentum tissue.

### Claim 3

A prosthesis for treating damaged biological tissue, comprising:
a mesh structure comprising a plurality of fibers comprising a composition comprising acellular ECM from a mammalian tissue source, poly(glycerol sebacate) (PGS) and at least one antibiotic selected from the group consisting of vancomycin and gentamicin.

### Claim 4 (depends on 3)

The prosthesis of claim 3, wherein said mammalian tissue source comprises tissue selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), mesothelial tissue, placental tissue, cardiac tissue, kidney tissue and omentum tissue.

### Claim 5

A cardiovascular prosthesis, comprising:
an ECM-mimicking composition comprising poly(glycerol sebacate) (PGS) and a cytokine,
said ECM-mimicking composition, when disposed proximate damaged biological tissue, being adapted to modulate inflammation of said damaged biological tissue.

### Claim 6 (depends on 5)

The cardiovascular prosthesis of claim 5, wherein said cytokine comprises an interleukin.

### Claim 7 (depends on 6)

The cardiovascular prosthesis of claim 6, wherein said interleukin is selected from the group consisting of interleukin-8 (IL-8) and interleukin-10 (IL-10).

### Claim 8

A cardiovascular prosthesis, consisting of:
an ECM/ECM-mimicking composition consisting of a first plurality of first particulate structures and a second plurality of second particulate structures,
said first plurality of first particulate structures consisting of acellular extracellular matrix (ECM) from a mammalian tissue source,
said second plurality of second particulate structures consisting of poly(glycerol sebacate) (PGS) and everolimus,
said first plurality of first particulate structures and said second plurality of second particulate structures, when disposed proximate damaged cardiovascular tissue, adapted to jointly induce remodeling of said damaged cardiovascular tissue,
said second plurality of second particulate structures, when disposed proximate said damaged cardiovascular tissue, further adapted to suppress hyperplasia.

### Claim 9

A cardiovascular prosthesis, consisting of:
a plurality of biodegradable particulate structures, each of said plurality of particulate structures consisting of a first tissue remodeling inducing composition and a second tissue remodeling inducing composition, said second tissue remodeling inducing composition being encased in said first tissue remodeling inducing composition, wherein each of said plurality of particulate structures comprises a core consisting of said second tissue remodeling inducing composition and an outer layer consisting of said first tissue remodeling inducing composition,
said first tissue remodeling inducing composition consisting of an ECM-mimicking composition, said ECM-mimicking composition consisting of poly(glycerol sebacate) (PGS) and everolimus, said everolimus consisting of greater than 0.001 wt. % of said ECM-mimicking composition,
said second tissue remodeling inducing composition consisting of acellular ECM derived from a mammalian tissue source,
said first remodeling inducing composition, when delivered to damaged cardiovascular tissue, adapted to induce a first level of remodeling of said damaged cardiovascular tissue and suppress hyperplasia,
said second tissue remodeling inducing composition, when delivered to said damaged cardiovascular tissue, adapted to modulate inflammation of said damaged cardiovascular tissue and induce a second level of remodeling of said damaged cardiovascular tissue.

### Claim 10

A cardiovascular prosthesis, comprising:
a particulate structure comprising a plurality of particulate structures, each of said plurality of particulate structures comprising a biological component and a polymer component,
said biological component comprising a biological composition comprising decellularized placental tissue,
said polymer component comprising a polymer composition comprising poly(glycerol sebacate) (PGS).

### Claim 11 (depends on 10)

The prosthesis of claim 10, wherein said biological composition further comprises a plurality of exosomes derived from a cell source selected from the group consisting of mesenchymal stem cells and embryonic stem cells.

### Claim 12 (depends on 10)

The prosthesis of claim 10, wherein said biological composition further comprises an HMG-CoA reductase inhibitor.

### Claim 13 (depends on 10)

The prosthesis of claim 10, wherein said HMG-CoA reductase inhibitor comprises (3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)py-ridin-3-yl]-3,5-dihydroxyhept-6-enoic acid (cerivastatin).

### Claim 14 (depends on 10)

The prosthesis of claim 10, wherein said polymer composition further comprises poly(ε-caprolactone) (PCL).

### Claim 15 (depends on 1)

The prosthesis of claim 1, wherein said biological component is encased in said polymer component.

### Claim 16 (depends on 1)

The prosthesis of claim 1, wherein the placental tissue is amniotic membrane tissue.

### Claim 17

A cardiovascular prosthesis, comprising:
an ECM-mimicking composition, said ECM-mimicking composition comprising a polymer component and a pharmacological component,
said polymer component comprising poly(glycerol sebacate) (PGS),
said pharmacological component comprising a biological composition comprising a corticosteroid selected from the group consisting of dexamethasone, dexamethasone phosphate, dexamethasone dipropionate, betamethasone, betamethasone phosphate, prednisolone, fluocinolone acetonide, endrisone, methylprednisolone suleptanate, alclometasone dipropionate, clobetasone butyrate, fluorometholone acetate, isoflupredone acetate, meclorisone, rimexolone and desoximetasone.

### Claim 18 (depends on 17)

The prosthesis of claim 17, wherein said pharmacological composition further comprises an HMG-CoA reductase inhibitor.

### Claim 19 (depends on 18)

The prosthesis of claim 18, wherein said HMG-CoA reductase inhibitor comprises (3R,5S,6E)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(propan-2-yl)py-ridin-3-yl]-3,5-dihydroxyhept-6-enoic acid (cerivastatin).

### Claim 20 (depends on 16)

The prosthesis of claim 16, wherein said ECM-mimicking composition further comprises a biological component.

### Claim 21 (depends on 20)

The prosthesis of claim 20, wherein said biological component comprises a biological composition.

### Claim 22 (depends on 21)

The prosthesis of claim 21, wherein said biological composition comprises extracellular matrix (ECM) from a mammalian tissue source selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), cardiac tissue, placental tissue, amniotic membrane tissue, and mesothelial tissue.

### Claim 23 (depends on 22)

The prosthesis of claim 22, wherein said biological composition further comprises a biologically active agent.

### Claim 24 (depends on 23)

The prosthesis of claim 23, wherein said biologically active agent comprises an exosome derived from a cell source selected from the group consisting of mesenchymal stem cells and embryonic stem cells.

### Claim 25 (depends on 23)

The prosthesis of claim 23, wherein said biologically active agent comprises a cytokine selected from the group consisting of interleukin-8 (IL-8) and interleukin-10 (IL-10).

### Claim 26 (depends on 23)

The prosthesis of claim 23, wherein said biologically active agent comprises a growth factor selected from the group consisting of a fibroblast growth factor-2 (FGF-2), transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-β), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), nerve growth factor (NGF), platelet derived growth factor (PDGF), tumor necrosis factor alpha (TNF-α) and placental growth factor (PLGF).

### Claim 27

A cardiovascular prosthesis, comprising:
a sheet structure comprising an ECM-mimicking composition, said ECM-mimicking composition comprising a polymer component and a pharmacological component,
said polymer component comprising poly(glycerol sebacate) (PGS),
said pharmacological component comprising a biological composition comprising a corticosteroid selected from the group consisting of dexamethasone, dexamethasone phosphate, dexamethasone dipropionate, betamethasone, betamethasone phosphate, prednisolone, fluocinolone acetonide, endrisone, methylprednisolone suleptanate, alclometasone dipropionate, clobetasone butyrate, fluorometholone acetate, isoflupredone acetate, meclorisone, rimexolone and desoximetasone.

### Claim 28 (depends on 27)

The prosthesis of claim 27, wherein said ECM-mimicking composition further comprises a biological component.

### Claim 29 (depends on 28)

The prosthesis of claim 28, wherein said biological component comprises a biological composition.

### Claim 30 (depends on 29)

The prosthesis of claim 29, wherein said biological composition comprises extracellular matrix (ECM) from a mammalian tissue source selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), cardiac tissue, placental tissue, amniotic membrane tissue, and mesothelial tissue.

### Claim 31 (depends on 30)

The prosthesis of claim 30, wherein said biological composition further comprises a biologically active agent.

### Claim 32 (depends on 31)

The prosthesis of claim 31, wherein said biologically active agent comprises an exosome derived from a cell source selected from the group consisting of mesenchymal stem cells and embryonic stem cells.

### Claim 33 (depends on 31)

The prosthesis of claim 31, wherein said biologically active agent comprises a cytokine selected from the group consisting of interleukin-8 (IL-8) and interleukin-10 (IL-10).

### Claim 34 (depends on 31)

The prosthesis of claim 31, wherein said biologically active agent comprises a growth factor selected from the group consisting of a fibroblast growth factor-2 (FGF-2), transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-β), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), nerve growth factor (NGF), platelet derived growth factor (PDGF), tumor necrosis factor alpha (TNF-α) and placental growth factor (PLGF).

### Claim 35

A biomaterial composition for treating damaged cardiovascular tissue, comprising:
an ECM-mimicking composition comprising poly(glycerol sebacate) (PGS) and an antifibrotic,
said antifibrotic comprising paclitaxel,
said biomaterial composition being configured to induce modulated healing when delivered to damaged biological tissue, said modulated healing comprising inflammation modulation of said damaged tissue and induced neovascularization, host cell proliferation, remodeling of the damaged tissue, and regeneration of new tissue and tissue structures.

### Claim 36 (depends on 35)

The composition of claim 35, wherein said ECM-mimicking composition further comprises poly(s-caprolactone) (PCL).

### Claim 37 (depends on 35)

The composition of claim 35, wherein said ECM-mimicking composition further comprises a HMG-CoA reductase inhibitor.

### Claim 38 (depends on 37)

The composition of claim 37, wherein said HMG-CoA reductase inhibitor comprises cerivastatin.

### Claim 39

A biomaterial composition for treating damaged cardiovascular tissue, comprising:
an ECM-mimicking composition comprising poly(glycerol sebacate) acrylate (PGSA) and an antifibrotic,
said antifibrotic comprising paclitaxel,
said biomaterial composition being configured to induce modulated healing when delivered to damaged biological tissue, said modulated healing comprising inflammation modulation of said damaged tissue and induced neovascularization, host cell proliferation, remodeling of the damaged tissue, and regeneration of new tissue and tissue structures.

### Claim 40 (depends on 39)

The composition of claim 39, wherein said ECM-mimicking composition further comprises a HMG-CoA reductase inhibitor.

### Claim 41 (depends on 40)

The composition of claim 40, wherein said HMG-CoA reductase inhibitor comprises cerivastatin.

### Claim 42

A biomaterial composition for treating damaged cardiovascular tissue, comprising:
an ECM/ECM-mimicking composition comprising acellular extracellular matrix (ECM) from a mammalian tissue source, poly(glycerol sebacate) (PGS) and an antifibrotic,
said antifibrotic comprising paclitaxel,
said biomaterial composition being configured to induce modulated healing when delivered to damaged biological tissue, said modulated healing comprising inflammation modulation of said damaged tissue and induced neovascularization, host cell proliferation, remodeling of the damaged tissue, and regeneration of new tissue and tissue structures.

### Claim 43 (depends on 42)

The composition of claim 42, wherein said mammalian tissue source is selected from the group consisting of small intestine submucosa, stomach submucosa, urinary bladder submucosa, cardiac tissue, placental tissue, mesothelial tissue and omentum tissue.

### Claim 44 (depends on 42)

The composition of claim 42, wherein said ECM-mimicking composition further comprises a HMG-CoA reductase inhibitor.

### Claim 45 (depends on 44)

The composition of claim 44, wherein said HMG-CoA reductase inhibitor comprises cerivastatin.
